Series
The Payer's Dilemma
MCR-04.01
Is MA Still Worth It?
The Strategic Recalculation for Insurers
MCR-04.02
Benefit Design 2026-2027
What Plans Will (and Won't) Offer
MCR-04.03
The Broker Compensation Wars
Court Ruling, DOJ Enforcement, and the Deregulation Pivot
MCR-04.04
The TPMO Ecosystem
Who Controls Medicare Enrollment and Why It Matters
MCR-04.05
The Independent Agent's Dilemma
Commissions, Ethics, and the Benefit Contraction Era
MCR-04.06
Regional Plans vs. National Giants
Who Survives the Rate Compression
MCR-04.07
Star Ratings in Transition
The Quality Bonus Payment Battlefield
MCR-04.08
MA Market Consolidation
Exit, M&A, and New Entrants
MCR-04.09
Part D in 2026-2027
Drug Negotiation, Formulary Disruption, and the BALANCE Bridge
MCR-04.10
Medicare Fraud, Waste, and Abuse
The $60 Billion Structural Problem
MCR-04.11
Private Equity in Medicare Delivery
Accountability, Quality, and the Care Model Question
MCR-04.12
The IRA Drug Negotiation Process
First Cohort MFPs, Manufacturer Litigation, and What Comes Next